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RESUMO: Substâncias inflamatórias como interleucinas (IL), fator alfa de necrose 
tumoral (TNF-α) e proteína-C reativa (CRP) desempenham papel importante na 
progressão da insuficiência cardíaca. Os objetivos desse estudo foram dois: 
investigar a concentração de citocinas circulantes em cães com doença mixomatosa 
da valva mitral (DMVM) em diferentes estágios, e acessar a relação entre essas 
substâncias e a morfologia e função cardíacas. Com esse intuito, doze cães com 
DMVM (7 em estágio B2; 5 em estágio C) e nove controles saudáveis foram 
submetidos à ecocardiografia transtorácica e tiveram as concentrações séricas de 
IL-1β, 4, 6, 10, TNF-α e CRP quantificadas. Os dados foram submetidos ao teste de 
normalidade de Shapiro-Wilk, os grupos foram comparados por meio da ANOVA ou 
Kruskal-Wallis de acordo com a distribuição, e os coeficientes de correlação obtidos 
pelo teste de Spearman. A concentração de IL-1β diferiu (P: 0,0056) entre os 
grupos. Ademais, houve correlação positiva entre IL-1β e o diâmetro ventricular 
esquerdo ao final da diástole (R: 0,56), relação átrio esquerdo aorta (R: 0,63) e 
parâmetros indicadores de congestão. Similarmente, a IL-4 exibiu correlação 
positiva de média a forte com parâmetros de remodelamento e congestão 
cardíacos, enquanto a IL-6 apresentou correlação negativa com a fração de 
encurtamento. Como conclusão principal, o nível de IL-1β aumenta em cães com 
DMVM e valores ainda maiores são observados nos animais sintomáticos.  
 




ABSTRACT: Inflammatory substances such as interleukins (IL), tumor necrosis 
factor alpha (TNF-α) and C-reactive protein (CRP) have been demonstrated to play 
a role in heart failure progression. The aims of this study were two-fold: to 
investigate the concentration of circulating cytokines in dogs with myxomatous mitral 
valve disease (MMVD) in different stages, and to assess the relationship between 
these substances and cardiac morphology and function. For this purpose, twelve 
dogs with MMVD (7 stage-B2; 5 stage-C) and nine healthy controls underwent a 
transthoracic echocardiogram and had their serum concentrations of IL-1β, 4, 6, 10, 
TNF-α and CRP assessed. Data was submitted to Shapiro-Wilk normality test, 
groups were compared with ANOVA or Krukal-Wallis test according to distribution, 
and correlation coefficients were obtained with Spearman test. The IL-1β levels were 
different (P: 0.0056) between groups. Also, a positive correlation existed between IL-
2 
Parasitological analysis of cress (Nasturtium officinale, Barbarea verna e Lepidium sativum) samples from Curitiba area, Brazil 
 
Archives of Veterinary Science, v.22, n.4, p.1-8, 2017. 
1β and left ventricular end-diastolic diameter (R: 0.56), left atrium-to-aorta ratio (R: 
0.63) and echocardiography congestion surrogates. Similarly, IL-4 exhibited 
moderate-to-strong positive correlation with parameters of cardiac remodeling and 
congestion, while IL-6 was negatively correlated with the shortening fraction (R: -
0.49). As the main conclusion, IL-1β levels increases in dogs with MMVD, and even 
higher levels are observed in overtly symptomatic animals. 
 






Myxomatous mitral valve disease 
(MMVD) is widely accepted as the most 
common acquired cardiac disease in 
dogs. The impaired leaflets coaptation 
ultimately leads to blood regurgitation 
from the left ventricle (LV) to the left 
atrium (LA) during ventricular systole 
(BORGARELLI et al., 2004; ATKINS et 
al., 2009).  
Blood regurgitation decreases 
cardiac output and triggers the activation 
of neuroendocrine mechanisms, leading 
to parasympathetic decline and 
upregulation of the sympathetic tone, 
which causes both LA and LV volume 
overload and clinical signs ascribed to 
congestive heart failure. Interestingly, 
many inflammatory substances, like 
endothelin (ET), interleukins (IL), tumor 
necrosis factor alpha (TNF-α) and C-
reactive protein (CRP) have been 
demonstrated to play a role in heart 
failure pathogenesis as well 
(FILIPPATOS et al., 2003; CHEN et al., 
2008; SLUPE et al., 2008).  Those 
inflammatory mediators are able to 
induce cardiomyocyte hypertrophy, 
activation of metalloproteinases, 
degradation of extracellular matrix, 
fibrosis, besides having negative 
inotropic effects (LEVINE et al., 1990; 
DUTKA et al., 1993; ORAL et al., 1995). 
The ET activates the necrosis 
factor, a transcription agent that 
increases the production of pro-
inflammatory substances (MULLER et 
al., 2003). In dogs affected by MMVD it 
was observed an augmentation in ET 
receptors expression on mitral valve 
leaflets (MOW et al., 1999; LU et al., 
2015). Similarly, a large population-
based study, the ¨InCHIANTI study¨ 
demonstrated that increased serum 
levels of interleukin-1β (IL-1β) in patients 
with heart failure correlates with its 
severity irrespective of its etiology (DI 
IORIO et al., 2003), and similar results 
were found in dogs (KICZAK et al., 
2008). Moreover, it was also 
demonstrated that interleukin-8 (IL-8) is 
upregulated in dogs with MMVD, 
increasing according to its severity 
(MAVROPOULOU et al., 2016).  
The CRP is a major acute phase 
protein in the dog, that is released from 
hepatic cells after stimulation by 
cytokines early in the course of the 
inflammatory process, and increased 
serum values have been recorded in 
dogs with acquired (RUSH et al., 2006; 
CUNNINGHAM et al., 2012; 
POLIZOPOULOU et al., 2015) and 
congenital (SAUNDERS et al., 2009) 
cardiac diseases.  
In chronic cardiac diseases such 
as MMVD, where clinical changes can 
be unapparent, periodic evaluation of 
biomarkers has been proposed as a 
complementary method for clinical and 
therapeutic monitoring and prognosis 
assessment in dogs (LU et al., 2015a; 
POLIZOPOULOU et al., 2015). 
Therefore, the aims of this study were 
two-fold: to investigate the concentration 
of circulating cytokines in dogs with 
MMVD in different stages, and to assess 
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the relationship between these 
substances and cardiac morphology and 
function assessed by echocardiography. 
 
MATERIAL AND METHODS 
 
This study had a prospective, 
cross-sectional and observational 
design, and was conducted at a 
veterinary teaching facility. All 
procedures were previously approved by 
the institutional Animal Use Committee 
(protocol #4628/13). The inclusion 
criteria included dogs with the diagnosis 
of MMVD based on both physical 
examination and a complete 
transthoracic echocardiogram. The 
exclusion criteria were altered laboratory 
analysis, including complete blood count 
(CBC) and biochemistry profile, as well 
as the diagnosis of MMVD with no 
cardiac remodeling and/or evidence of 
cardiac diseases other than MMVD. 
Once enrolled, dogs were categorized in 
groups that represented the disease 
stages, according to the American 
College of Veterinary Internal Medicine 
consensus statement on canine valvar 
disease (ATKINS et al, 2009). 
Furthermore, normal age-matched dogs 
were recruited from the institution’s 
experimental kennel as healthy controls. 
The echocardiogram was 
performed with the dogs restrained in 
right and left lateral recumbencies, using 
an ultrasound machine equipped with 
5.0-7.5 MHz phased-array transducer 
(Siemens X300 Premium Edition, United 
States). Images were acquired and 
stored for offline measurements. The 
echocardiographic parameters aimed at 
assessing systolic function and cardiac 
morphology included the left ventricular 
end-diastolic (LVd) and end-systolic 
(LVs) diameters, the left atrium-to-aorta 
ratio (LA/Ao), and the fractional 
shortening (FS), which were all 
documented from transverse images 
obtained from the right parasternal 
window. Diastolic assessment included 
the ratio between left ventricular rapid 
and slow filling velocities (Em/Am), 
isovolumetric relaxation time (IVRT), and 
Em-to-IVRT ratio, which were measured 
from either apical 4- or 5-chamber 
images obtained from the left 
parasternal window. Also, tissue doppler 
imaging was used to acquire mitral 
annular velocity at early (ETDI) and late 
(ATDI) diastole, which allowed the 
calculation of Em-to-ETDI ratio. All 
echocardiographic data represented the 
mean of at least three consecutive 
cardiac cycles, and were obtained in 
accordance with the guidelines 
described elsewhere (BOON, 2011). 
Blood samples were drawn 
aseptically from the jugular vein and 
stored in tubes without anticoagulant, 
which were immediately taken to the 
laboratory to undergo centrifugation. 
Several aliquots of serum were obtained 
and stored at -80°C until the batch 
analyses were performed. Immediately 
before the procedures, the aliquots were 
thawed and laboratory processing 
followed the kit manufacturer’s 
instructions. 
Enzyme-linked immunosorbent 
assays were used to determine the 
serum concentrations of IL-1β 
(SEA563Ca, USCN®, China), IL-4 
(SEA077Ca, USCN®, China) and C-
reactive protein (CYT296, Millipore®, 
USA). Once the reactions were over, the 
software MultiCalc (MultiCalc®, 
Florianópolis, Brazil) was used to 
calculate the substance’s concentration 
from the intensity of color documented in 
an ELISA reader (Stat Fax 2600, 
Awareness®, Palm City, USA). The 
serum concentrations of IL-6, IL-10 and 
TNF-α  were determined with an 
automatic analyzer (Luminex 200, 
Luminex Corporation, Austin, USA) 
using a commercially-available multiplex 
immunoassay (CCYTO-90K Milliplex 
MAP, Millipore®, USA). The minimum 
detectable concentrations of IL 1β, IL 4, 
IL 6, IL 10, TNF-α and CRP were at 
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least 5.8 pg/mL, 6.0 pg/mL, 1.98 pg/mL, 
0.9 pg/mL, 0.7 pg/mL and 3.6 µg/mL, 
respectively. All results represent the 
average of the concentrations obtained 
from two duplicate samples. 
 Data were submitted to the 
Shapiro-Wilk normality test to investigate 
the distribution. Whenever a normal 
distribution was attained, Student’s T 
test was used to compare control and 
MMVD dogs. Also, the analysis of 
variance (ANOVA) followed by the post-
hoc Tukey test was used to further 
compare healthy and MMVD dogs 
divided according to stages. Whenever 
data was not normally distributed, 
normal and diseased animals were 
compared with the Mann-Whitney test, 
and further comparison between healthy 
dogs and MMVD animals separated in 
stages was performed with the Kruskal-
Wallis test followed by Dunn’s multiple 
comparisons test. Finally, correlations 
between the serum concentration of the 
inflammatory substances and the 
echocardiographic data were 
investigated using the Spearman test. 
All analyses were done with the software 
Prism Windows 3.0, (GraphPad®, San 
Diego, USA), and significance was 




Twelve adult dogs (3.0-17.3 kg) 
with MMVD and remodeled hearts were 
recruited at the end of the study. Cardiac 
dilatation was based on the 
documentation of an increased LA/Ao 
ratio (>1.4) on the echocardiogram. Five 
dogs (3.0-14.0 kg) had overt clinical 
signs attributable to heart failure (stage 
C), while seven animals (10.2-14.0 kg) 
were still asymptomatic (stage B2). Also, 
nine adult dogs (10.2-17.3 kg) that 
presented no murmur on auscultation 
nor exhibited any signs that could be 
ascribed to heart failure were recruited 
as healthy controls. No differences in 
body weight existed between groups (P: 
0.40).The serum concentration of IL-1β 
was considered different between 
control (0.40 pg/mL), stage B2 (10.47 
pg/mL) and stage C (17.31 pg/mL) 
groups (P: 0.0015) (figure 1).  
 
 
Figure 1: Boxplots illustrating the statistically different 
plasma concentration of interleukin 1β in healthy dogs and 
dogs with myxomatous mitral valve disease. Medians, 
interquartile ranges and minimum-maximum values are 
shown. 
 
Concentrations of IL-4, 10 and 
CRP were considered similar among 
groups, even though there is a clear 
trend in increasing levels according to 
MMVD severity. On the other hand, 
values of IL-6 and TNF-α seems to 
decrease with the progression of the 
disease, in spite of no statistical 
difference being recorded between 
groups. Results are summarized in table 
1. 
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IL-1β attained a moderate-to-
strong correlation with the 
echocardiographic parameters. A 
positive correlation was documented 
between IL-1β and LVd, LA/Ao, 
Em/IVRT and Em/ETDI, whereas a 
negative correlation existed with IVRT. 
Also, the concentration of IL-4 was 
positively correlated with LA/Ao (R: 0.47) 
and Em/ETDI (R: 0.70), while a negative 
correlation was documented between IL-
6 and FS (R: -0.49). Scatterplots 
showing all significant correlations with 
their respective identity lines, 95% 
confidence bands and correlation 
coefficients are represented in figure 2.  
 
 
Figure 2. Scatterplots showing the moderate-to-strong 
correlations between the echocardiographic data and the 
serum concentration of interleukins 1β, 4 and 6. Best-fit lines 
and their 95% confidence intervals are shown. (A) interleukin 
1β versus the left ventricular internal diameter in diastole; (B) 
interleukin 1β versus the left atrium-to-aorta ratio; (C) 
interleukin 1β versus the isovolumic relaxation time; (D) 
interleukin 1β versus the left ventricular rapid filling velocity-
to-isovolumic relaxation time ratio; (E) interleukin 1β versus 
the left-ventricular rapid filling velocity-to-mitral annular 
velocity at early diastole; (F) interleukin 4 versus the the left 
atrium-to-aorta ratio; (G) interleukin 4 versus the left-
ventricular rapid filling velocity-to-mitral annular velocity at 





It was already demonstrated that 
IL-1β mRNA expression elevates even 
in early stages of cardiac diseases in 
dogs, with gradual increases until end-
stage left ventricle dysfunction (KICZAK 
et al., 2008, 2015). Our results 
demonstrate a progressive 
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augmentation in IL-1β along MMVD 
stages. Also, the diseased groups (B2 
and C) had higher levels in comparison 
with healthy dogs.  
 The moderate-to-strong positive 
correlation coefficients obtained 
between IL-1β and echocardiography 
surrogates of volume overload (LVd; 
LA/Ao) and congestion (Em/TRIV; 
Em/ETDI), suggest a relationship among 
higher levels of that cytokine and the 
progression of mitral insufficiency 
towards heart failure. According to 
previously published studies, the 
biological effects of pro-inflammatory 
cytokines, such as IL-1β, results in 
cardiomyocyte hypertrophy and atrophy, 
leading to cardiac fibrosis and 
inflammatory infiltrates (THAIK et al., 
1995; DINARELLO et al., 1996; BARTH 
et al., 2000; KICZAK et al., 2008). 
Moreover, IL-1β was shown to 
significantly upregulate the brain 
natriuretic peptide (BNP) transcription - 
a neurohormone released by ventricles 
in response to volume or pressure 
overload, thus being used as biomarker 
of cardiac damage - in atrial and 
ventricular cardiomyocytes (HE et al., 
1999).  
 The interleukin-4 has multiple 
biological effects as well, promoting 
tissue fibrotic remodeling in diseases 
involving lungs (WALFORD et al., 2013), 
skin (ZUBER et al., 2006) and liver (SHI 
et al., 1997). Studies have shown a 
positive correlation between circulating 
IL-4 levels and cardiac fibrotic 
remodeling in both human beings 
(ROSELLÓ-LLETÍ et al., 2007; 
CATAPANO et al., 2008) and laboratory 
animals (LEVICK et al., 2009; CIESLIK 
et al., 2011; PENG et al., 2016). Aside 
from the positive correlation among 
echocardiographic data of volume 
overload (LA/Ao) and congestion 
(Em/ETDI) and IL-4 levels, we observed 
a clear trend of increase in IL-4 
according to the progression of MMVD, 
in spite of no statistical difference being 
documented between disease stages.   
 Owing to MMVD progression, the 
organism activates neuroendocrine 
compensatory mechanisms, in an 
attempt to maintain the stroke volume 
and arterial blood pressure within the 
normal range. The autonomic 
dysfunction caused by heart failure 
enhances the sympathetic tone, which 
increases the circulating levels of 
norepinephrine (HÄGGSTRÖM; KVART; 
PEDERSEN, 2005). Also, the activation 
of the renin-angiotensin-aldosterone 
system (RAAS) promotes sodium and 
water reabsorption, leading to preload 
improvement (HÄGGSTRÖM; KVART; 
PEDERSEN, 2005). However, these two 
compensatory actions trigger the 
Franking-Starling mechanism, resulting 
in increased fraction of shortening (FS) 
thereafter. The moderate negative 
correlation obtained between IL-6 levels 
and FS was expected, once advanced 
stages of MMVD dogs usually exhibit 
higher FS, and lower levels of IL-6 were 
detected in stage C. However, the 
relationship between IL-6 and 
progression of canine cardiac diseases 
remains unclear, and studies are 
conflicting. Although the IL-6 plasma 
levels increased in heart failure dogs 
when compared with control group in 
one study (TANAKA-ESPOSITO et al., 
2014), Zois et al. (2012) did not found 
difference between IL-6 levels in MMVD 
dogs according to stages.  
 The small number of dogs 
according to MMVD stages, and mostly 
important, the absence of animals in 
stage D, may have a negative impact in 
our results, once some inflammatory 
substances, such as IL-4, IL-10 and 
TNF-α, showed a trend of variation but 
no statistical difference was actually 
found among groups. Moreover, a 
longitudinal study design could probably 
better elucidate the role of IL-6, IL-10, 
TNF-α and CRP in the pathogenesis of 
heart failure. The results of this research 
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Our major findings are as follows. 
(1) The serum levels of interleukin 1β 
increases in dogs with myxomatous 
mitral valve disease, and even higher 
levels are observed in overtly 
symptomatic animals; (2) there is an 
important correlation between cardiac 
remodeling and congestion as assessed 
by echocardiography and the circulating 
levels of IL-1β and IL-4; (3) the serum 
levels of interleukin-6 and the left-
ventricular shortening fraction are 
negatively correlated.   
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